Adjuvant Alectinib in ALK-Rearranged NSCLC — Here and Now
Mené sur 257 patients atteints d'un cancer du poumon non à petites cellules ALK+ ayant été réséqué, cet essai randomisé de phase III compare l'efficacité, du point de vue de la survie sans maladie, et la toxicité de l'alectinib et d'une chimiothérapie à base de sels de platine en traitement adjuvant
In 2009, the groundbreaking Iressa Pan-Asia Study (IPASS)1 showed the activity of gefitinib, a first-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), and marked a pivotal shift in the treatment of advanced non–small-cell lung cancer (NSCLC) toward precision medicine. The trial highlighted the importance of identifying actionable genetic alterations in approximately a third of the cases, predominantly adenocarcinomas. This advancement underscores the necessity for detailed molecular analysis of tumors to personalize therapy. In addition, the emergence of different TKIs then allowed a focus on the management of brain metastases, which occur in 20 to 60% of patients with . .